WALTHAM, MA • 2021-06-01

BostonGene Announces Acceptance of Abstracts to 2021 ASCO Annual Meeting

5 min to read

BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients
WALTHAM, MA − June 1, 2021

BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that two abstracts have been accepted for online publication for the 2021 ASCO Annual Meeting.

“We are pleased to have multiple abstracts accepted for online publication,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our findings underscore the importance of the application of novel and cutting-edge analytical tools to understand the composition and activity of the tumor and the microenvironment, which will improve treatment outcomes for cancer patients.”

The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

Details about the abstracts selected for publication can be found below:

Abstract Number: e15050
Title: The development of a computational machine learning tool to decipher malignant cell gene expression from complex tumor tissue

Complex tumor tissue is composed of malignant cells and diverse tumor microenvironment (TME) cellular populations. The percentage of malignant cells present in tumor tissue varies by cancer type, with percentages sometimes falling below 10%. TME cellular transcripts may comprise the majority of the total transcripts in a tumor, potentially resulting in biases during biomarker development and for clinical decision-making. A computational tool was created to “subtract” TME-specific gene expression from total gene expression in an array of solid tumors, producing in silico “purified” malignant cell gene expression.

Abstract Number: e15085
Title: Analytical and clinical validation of the BostonGene Tumor Portrait assay

Analysis of the genetic and transcriptomic profile of solid tumors using next-generation sequencing (NGS) assays is fundamental to propel precision medicine into clinical practice. NGS technology applied to tumor analysis allows for the characterization of somatic alterations, clonality, altered gene expression, and other parameters using a small amount of tissue. The BostonGene Tumor Portrait Tests™, which integrate whole-exome sequencing (WES) and mRNA sequencing (RNA-seq), were developed to uncover cancer-promoting and -suppressing activity of the tumor and the tumor microenvironment (TME).


About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com